Therapeutic Response

HER2-negative and PD-L1 (CPS) >= 5 status confers therapeutic sensitivity to Capecitabine in combination with Nivolumab and Oxaliplatin in patients with Esophageal Adenocarcinoma.

Statements

Source and description
Opdivo (nivolumab) [product information]. EMA. The European Medicines Agency (EMA) has authorized nivolumab in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the first-line treatment of adult patients with HER2-negative advanced or metastatic gastric, gastro-esophageal junction, or esophageal adenocarcinoma whose tumors express PD-L1 with a combined positive score (CPS) >= 5. This indication is based on CA209649, a phase 3, randomized, open-label study where the choice of chemotherapy was FOLFOX (oxaliplatin, leucovorin, and fluorouracil) or CapeOX (capecitabine and oxaliplatin).
Nivolumab and XELOX Therapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved nivolumab in combination with fluoropyrimidine and platinum-based combination chemotherapy as a treatment option for the first-line treatment of adult patients with HER-2 negative advanced or metastatic gastric cancer (GC), gastroesophageal junction cancer (GEJC), or esophageal adenocarcinoma (EAC), whose tumours express PD-L1 (CPS) >= 5. This treatment regimen is specifically for nivolumab and XELOX (capecitabine and oxaliplatin) therapy, though the treatment regimen specifically notes that other evidence based platinum and fluoropyrimidine based regimens may be used as the EMA licensed indication does not define the platinum and fluoropyrimidine based chemotherapy.